Renaissance Technologies Portfolio holdings
Renaissance Technologies LLC, founded in 1982 by mathematician James Simons as Monemetrics and headquartered in East Setauket, New York, is a legendary quantitative hedge fund managing around $65 billion in assets as of late 2024, renowned for its pioneering use of mathematical models and algorithms in trading. Starting with currency trading and evolving into a secretive powerhouse under its flagship Medallion Fund—launched in 1988—the firm employs PhDs, physicists, and computer scientists to analyze vast datasets, executing high-frequency trades across equities, futures, and derivatives with returns averaging over 66% annually before fees from 1988 to 2018. Simons, who stepped down as chairman in 2021, built a culture of intellectual rigor, limiting Medallion to employees and insiders since 1993 while offering institutional funds like the Renaissance Institutional Equities Fund (RIEF) to outsiders. Now led by Peter Brown and Robert Mercer’s successors, Renaissance remains a benchmark for quant investing, blending academic precision with a low-profile, extraordinarily profitable legacy despite occasional regulatory scrutiny.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$628M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$567M |
| 3 |
Biogen
BIIB
|
+$405M |
| 4 |
UnitedHealth
UNH
|
+$392M |
| 5 |
Walmart Inc
WMT
|
+$301M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Apple
AAPL
|
+$451M |
| 2 |
PepsiCo
PEP
|
+$382M |
| 3 |
Philip Morris
PM
|
+$256M |
| 4 |
Roku
ROKU
|
+$252M |
| 5 |
RHT
Red Hat Inc
RHT
|
+$248M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 18.91% |
| 2 | Technology | 12.35% |
| 3 | Consumer Discretionary | 10.31% |
| 4 | Financials | 9.99% |
| 5 | Consumer Staples | 8.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2826
American Realty Investors
ARL
$246M
| $569K | ﹤0.01% |
37,000
-2,600
| -7% | -$37.3K |
|
|
CCM
2827
Concord Medical Services
CCM
$19.2M
| $565K | ﹤0.01% |
23,430
-320
| -1% | -$8.13K |
|
|
DSKE
2828
DELISTED
Daseke, Inc. Common Stock
DSKE
| $563K | ﹤0.01% |
225,100
+38,900
| +21% | +$109K |
|
2829
T. Rowe Price
TROW
$23.9B
| $560K | ﹤0.01% |
4,900
-132,061
| -96% | -$14.7M |
|
2830
Alaunos Therapeutics
TCRT
$4.59M
| $559K | ﹤0.01% |
871
-504
| -37% | -$400K |
|
|
YARW
2831
Yarrow Bioscience, Inc. Common Stock
YARW
$23.4M
| $559K | ﹤0.01% |
35
+4
| +13% | +$64.6K |
|
2832
Monolithic Power Systems
MPWR
$70.1B
| $558K | ﹤0.01% |
3,586
-65,500
| -95% | -$9.79M |
|
2833
Danaos Corp
DAC
$2.58B
| $554K | ﹤0.01% |
61,531
+40,166
| +188% | +$320K |
|
2834
SEACOR Marine Holdings
SMHI
$256M
| $551K | ﹤0.01% |
43,872
+7,100
| +19% | +$93.5K |
|
2835
Purple Innovation
PRPL
$35.3M
| $548K | ﹤0.01% |
+2,912
| New | +$534K |
|
2836
BioXcel Therapeutics
BTAI
$24.9M
| $547K | ﹤0.01% |
4,856
+381
| +9% | +$60.1K |
|
2837
J. Jill
JILL
$272M
| $547K | ﹤0.01% |
57,620
-14,220
| -20% | -$145K |
|
2838
QuidelOrtho
QDEL
$1.14B
| $546K | ﹤0.01% |
8,900
-106,187
| -92% | -$6.39M |
|
|
SJI
2839
DELISTED
South Jersey Industries, Inc.
SJI
| $546K | ﹤0.01% |
16,600
-60,500
| -78% | -$1.98M |
|
|
CVSA
2840
Covista Inc
CVSA
$4.25B
| $545K | ﹤0.01% |
+14,300
| New | +$642K |
|
|
ICON
2841
DELISTED
Iconix Brand Group, Inc.
ICON
| $545K | ﹤0.01% |
306,078
+32,715
| +12% | +$44.1K |
|
|
BSCM
2842
DELISTED
Invesco BulletShares 2022 Corporate Bond ETF
BSCM
| $544K | ﹤0.01% |
25,300
-8,494
| -25% | -$182K |
|
|
HEP
2843
DELISTED
Holly Energy Partners, L.P.
HEP
| $542K | ﹤0.01% |
+21,431
| New | +$588K |
|
|
BDCL
2844
DELISTED
2Leveraged Long ETRACS Linked to the Wells Fargo Business Dev
BDCL
| $541K | ﹤0.01% |
+36,832
| New | +$522K |
|
2845
Tiptree Inc
TIPT
$662M
| $538K | ﹤0.01% |
73,858
+19,258
| +35% | +$130K |
|
2846
iShares Russell 2000 Value ETF
IWN
$14.3B
| $537K | ﹤0.01% |
+4,500
| New | +$532K |
|
2847
Champion Homes
SKY
$4.37B
| $536K | ﹤0.01% |
+17,800
| New | +$515K |
|
2848
ImmuCell
ICCC
$101M
| $535K | ﹤0.01% |
96,106
+4,100
| +4% | +$24K |
|
|
ORKA
2849
Oruka Therapeutics
ORKA
$5.82B
| $535K | ﹤0.01% |
8,341
+1,634
| +24% | +$120K |
|
2850
Maximus
MMS
$3.17B
| $533K | ﹤0.01% |
6,900
-23,000
| -77% | -$1.75M |
|
Similar funds
Renaissance Technologies's Q3 2019 Portfolio in Review
As of Q3 2019, Renaissance Technologies held 3,920 positions worth $118B, up 4% from $114B the previous quarter. Its ten largest holdings account for 11% of the portfolio.
Renaissance Technologies deployed $5.29B of net new capital in Q3 2019, opening 406 new positions and adding to 1,848 existing holdings. Its largest new stake was UnitedHealth: 1,624,826 shares worth $353M.
By sector, the portfolio is most concentrated in Healthcare at 19% of assets, up from 18% a quarter earlier, followed by Technology and Consumer Discretionary.
On the sell side, the largest reduction was Apple, an estimated $451M trimmed.
- Renaissance Technologies's largest Q3 2019 buy was UnitedHealth: 1,624,826 shares worth $353M.
- Renaissance Technologies added most to Celgene Corp in Q3 2019, an estimated $628M increase.
- Renaissance Technologies's biggest Q3 2019 reduction was Apple, cutting an estimated $451M.
- Renaissance Technologies fully exited Red Hat Inc in Q3 2019, selling an estimated $248M.
- Renaissance Technologies's ten largest holdings make up 11% of its $118B portfolio in Q3 2019.
- Renaissance Technologies opened 406 new positions and closed 522 in Q3 2019.
- Renaissance Technologies's portfolio value rose 4% quarter-over-quarter to $118B.
Based on Renaissance Technologies's 13F filing for Q3 2019, filed 13 Nov 2019.